🔎 Trials Near Me

Hem › Metastaserande cancer › Tennessee › Nashville

Kliniska studier för Metastaserande cancer i Nashville, TN

70 studier för Metastaserande cancer söker deltagare vid platser i och runt Nashville (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.

Officiell studietext (engelska)

Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

RekryterarFas 1/2
  • Avenzo Therapeutics Recruiting Site, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 5 okt. 2026 · NCT07193511

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

RekryterarFas 3
  • Sarah Cannon Research Institute, Nashville
  • Tennessee Oncology, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 5 okt. 2026 · NCT07562152

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

RekryterarFas 2
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
  • Vanderbilt University/Ingram Cancer Center, Nashville
Alla åldrar · Alla kön · Uppdaterad 5 okt. 2026 · NCT05564377

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

RekryterarFas 1
  • Tennessee Oncology, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT06270706

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

RekryterarFas 1
  • Sarah Cannon Research Institute, Nashville
  • Tennessee Oncology PLLC, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

RekryterarFas 1/2
  • Sarah Cannon Research Institute, Nashville
Ålder 12 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT04585750

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

RekryterarFas 1
  • Sarah Cannon Research Institute (SCRI), Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT06234605

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

RekryterarFas 1
  • Sarah Cannon Research Institute (SCRI), Nashville
Ålder 19 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT06586957

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

RekryterarFas 1
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT06625775

A Study of ASP3082 in Adults With Advanced Solid Tumors

RekryterarFas 1
  • Vanderbilt University Medical Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT05382559

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

RekryterarFas 2/3
  • Henry-Joyce Cancer Clinic, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT06943755

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

RekryterarFas 1
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
  • Vanderbilt University/Ingram Cancer Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT05803382

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

RekryterarFas 3
  • Henry-Joyce Cancer Clinic, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT07222800

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

RekryterarFas 1
  • Sarah Cannon Research Institute, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT07277413

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

RekryterarFas 2/3
  • Henry-Joyce Cancer Clinic, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06989437

A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

RekryterarFas 1
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07612176

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

RekryterarFas 3
  • SCRI Oncology Partners, Nashville
  • Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology, Nashville
  • Tennessee Oncology, PLLC - Saint Thomas West, Nashville
  • och 3 fler
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07222566

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

RekryterarFas 1/2
  • Sarah Cannon Research Institute, Nashville
Ålder 12 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT05118789

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

RekryterarFas 3
  • Vanderbilt University Medical Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07213804

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

RekryterarFas 3
  • Sarah Cannon Research Institute, Nashville
  • SCRI Oncology Partners, Nashville
  • Tennessee Oncology, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07218380

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

RekryterarFas 3
  • Sarah Cannon Research Institute SCRI, Nashville
  • Nashville General Hospital, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07174336

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

RekryterarFas 1/2
  • Sarah Cannon Research Institue, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06128551

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

RekryterarFas 1
  • Tennessee Oncology PLLC, Nashville
Ålder 18 till 99 · Alla kön · Uppdaterad 21 sep. 2026 · NCT07403721

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

RekryterarFas 1/2
  • Tennessee Oncology, PLLC, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 21 sep. 2026 · NCT07629960

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

RekryterarFas 1/2
  • Sarah Cannon Research Institute, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 18 sep. 2026 · NCT05267626

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

RekryterarFas 1/2
  • Sarah Cannon Research Institute, Nashville
  • SCRI Oncology Partners, Nashville
  • Tennessee Oncology, PLLC- Elliston Place Plaza, Nashville
  • och 11 fler
Ålder 18 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT07227415

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

RekryterarFas 1/2
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 16 sep. 2026 · NCT06566079

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

RekryterarFas 1/2
  • Clinical Study Site, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 10 sep. 2026 · NCT07335497

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

RekryterarFas 1
  • Sarah Cannon Research Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT06440005

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

RekryterarFas 1
  • Sarah Cannon Research Institute, Nashville
  • SCRI Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT06561685

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

RekryterarFas 3
  • Research Site, Nashville
Ålder 18 till 130 · Alla kön · Uppdaterad 8 sep. 2026 · NCT07647328

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

RekryterarFas 3
  • Tennessee Oncology, Nashville
  • USO - US Oncology Research Network, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT06119581

NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

RekryterarFas 1
  • Sarah Cannon Research Institute, Nashville
Ålder 19 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT07563829

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

RekryterarFas 2
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
  • Vanderbilt University/Ingram Cancer Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 4 sep. 2026 · NCT06311214

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

RekryterarFas 1
  • Sarah Cannon Research Institute-Tennessee Oncology, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 2 sep. 2026 · NCT04913285

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

RekryterarFas 2
  • Vanderbilt-Ingram Cancer Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 21 aug. 2026 · NCT06769698

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

RekryterarFas 1
  • Sarah Cannon and HCA Research Institute, Nashville
  • Tennessee Oncology, Nashville
  • Vanderbilt University Medical Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 20 aug. 2026 · NCT05614739

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

RekryterarFas 2
  • Research Site, Nashville
Ålder 18 till 130 · Alla kön · Uppdaterad 18 aug. 2026 · NCT06792695

FOG-001 in Locally Advanced or Metastatic Solid Tumors

RekryterarFas 1/2
  • Sarah Cannon Research Institute, Nashville
  • Vanderbilt Ingram Cancer Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 17 aug. 2026 · NCT05919264

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

RekryterarFas 1/2
  • Vanderbilt University/Ingram Cancer Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 31 juli 2026 · NCT05691491

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

RekryterarFas 1/2
  • SCRI Oncology Partners, Nashville
  • Vanderbilt Medical Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 30 juli 2026 · NCT04657068

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

RekryterarFas 3
  • Research Site, Nashville
Ålder 18 och äldre · Kvinnor · Uppdaterad 29 juli 2026 · NCT07044336

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

RekryterarFas 1
  • Investigative Site #102, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 23 juli 2026 · NCT06545942

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

RekryterarFas 1
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 15 juli 2026 · NCT06657144

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

RekryterarFas 1/2
  • Sara Cannon Research Institute Tennessee, Nashville
Ålder 12 och äldre · Alla kön · Uppdaterad 14 juli 2026 · NCT05533697

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

RekryterarFas 1
  • Exelixis Clinical Site #3, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 24 juni 2026 · NCT06952010

A Study of LY4175408 in Participants With Advanced Cancer

RekryterarFas 1
  • Sarah Cannon Research Institute, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 23 juni 2026 · NCT07046923

CT-95 in Advanced Cancers Associated With Mesothelin Expression

RekryterarFas 1
  • Context Investigational Site, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 12 juni 2026 · NCT06756035

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

RekryterarFas 1
  • Research Site, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 10 juni 2026 · NCT06835569

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

RekryterarFas 1
  • Sarah Cannon Research Institute, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 3 juni 2026 · NCT06040541

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

RekryterarFas 1
  • Vanderbilt University Medical Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 2 juni 2026 · NCT06917079

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

RekryterarFas 1/2
  • Sarah Cannon, Nashville
Ålder 12 och äldre · Alla kön · Uppdaterad 27 maj 2026 · NCT05384626

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

RekryterarFas 1/2
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 19 maj 2026 · NCT05431270

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

RekryterarFas 1/2
  • Sarah Cannon Research Institute, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 15 maj 2026 · NCT05379985

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

RekryterarTidig fas 1
  • Vanderbilt University Medical Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 8 maj 2026 · NCT06828588

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

RekryterarFas 1/2
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 22 apr. 2026 · NCT07020221

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

RekryterarFas 2/3
  • Sarah Cannon Research Institute, Nashville
  • Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic), Nashville
Alla åldrar · Alla kön · Uppdaterad 2 apr. 2026 · NCT06581406

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

RekryterarFas 1
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 20 mars 2026 · NCT05948865

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

RekryterarFas 1
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 25 feb. 2026 · NCT06521554

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

RekryterarFas 1
  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
  • Vanderbilt University Medical Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 13 feb. 2026 · NCT06778863

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

RekryterarFas 3
  • Vanderbilt University Medical Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 6 feb. 2026 · NCT06127407

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

RekryterarFas 1
  • Urology Associates PC, Nashville
Ålder 18 och äldre · Män · Uppdaterad 4 feb. 2026 · NCT04729114

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RekryterarFas 1
  • Vanderbilt-Ingram Cancer Center, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 19 dec. 2025 · NCT05270213

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

RekryterarFas 1
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 16 dec. 2025 · NCT06108050

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

RekryterarFas 1
  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
Ålder 18 till 99 · Alla kön · Uppdaterad 3 dec. 2025 · NCT07021898

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

RekryterarFas 1/2
  • SCRI Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 28 nov. 2025 · NCT07136181

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RekryterarObservationsstudie
  • Massive Bio SYNERGY-AI site, Nashville
Alla åldrar · Alla kön · Uppdaterad 28 okt. 2025 · NCT03452774

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

RekryterarFas 1
  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
Ålder 18 och äldre · Alla kön · Uppdaterad 1 juli 2025 · NCT06415487

Metastaserande cancer-studier i andra städer

Andra studier i Nashville

Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.